Year archive

Innovent Biologics, Inc. — 2024 filings

All 63 regulatory filings released by Innovent Biologics, Inc. (1801) in 2024, sourced directly from the official regulator.

63 Filings

2024 Period

2024 filings (63)

Filing	Released	Lang
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Governance Information	2024-12-27	English
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES Board/Management Information	2024-12-27	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES ROS1 INHIBITOR DOVBLERON (TALETRECTINIB ADIPATE CAPSULE) Regulatory Filings	2024-12-20	English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES Share Issue/Capital Change	2024-12-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024 Regulatory Filings	2024-12-05	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED CONDITIONAL APPROVAL FOR TYVYT (SINTILIMAB INJECTION) IN COMBINATION WITH ELUNATE (FRUQUINTINIB) FOR THE TREATMENT OF ADVA Regulatory Filings	2024-12-03	English
VOLUNTARY ANNOUNCEMENT - FIRST-TIME INCLUSION OF SINTBILO (TAFOLECIMAB INJECTION) AND NEW INDICATION FOR OLVEREMBATINIB IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST (2024 VERSION) Regulatory Filings	2024-11-28	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024 Regulatory Filings	2024-11-06	English
TERMINATION OF CONNECTED TRANSACTION Capital/Financing Update	2024-11-03	English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE THIRD QUARTER OF 2024 Capital/Financing Update	2024-10-30	English
CONNECTED TRANSACTION - PROPOSED SUBSCRIPTION AND DEEMED DISPOSAL OF EQUITY INTEREST IN A SUBSIDIARY Capital/Financing Update	2024-10-25	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024 Regulatory Filings	2024-10-07	English
2024 INTERIM REPORT Interim / Quarterly Report H1 2024	2024-09-27	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR PICANKIBART FOR MODERATE TO SEVERE PLAQUE PSORIASIS Regulatory Filings	2024-09-26	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024 Regulatory Filings	2024-09-06	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Governance Information	2024-08-30	English
CHANGE IN COMPOSITION OF BOARD COMMITTEES Board/Management Information	2024-08-30	English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES Remuneration Information	2024-08-30	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 Interim / Quarterly Report H1 2024	2024-08-28	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED CHINA'S FIRST KRAS G12C INHIBITOR DUPERT Regulatory Filings	2024-08-21	English
DATE OF BOARD MEETING Regulatory Filings	2024-08-14	English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE SECOND QUARTER OF 2024 Regulatory Filings	2024-08-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024 Regulatory Filings	2024-08-06	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION OF MAZDUTIDE FOR TYPE 2 DIABETES Regulatory Filings	2024-08-01	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024 Regulatory Filings	2024-07-05	English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 21, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-21	English
Amended and Restated Memorandum and Articles of Association Governance Information	2024-06-21	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 21, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-21	English
GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARES Share Issue/Capital Change	2024-06-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024 Share Issue/Capital Change	2024-06-07	English
PROPOSED GRANTS OF RESTRICTED SHARES TO DIRECTORS UNDER 2020 RS PLAN & ADOPTION OF 2024 SHARE SCHEME Regulatory Filings	2024-06-04	English
Form of Proxy for use at the Extraordinary General Meeting to be held on Friday, June 21, 2024 Proxy Solicitation & Information Statement	2024-06-04	English
NOTICE OF EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2024-06-04	English
(1) PROPOSED GRANTS OF RESTRICTED SHARES TO DIRECTORS UNDER THE 2020 RS PLAN, (2) PROPOSED ADOPTION OF THE 2024 SHARE SCHEME, AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2024-06-04	English
Form of Proxy for use at the Annual General Meeting to be held on Friday, June 21, 2024 AGM Information	2024-05-29	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2024-05-29	English
(1) PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, (2) PROPOSED RE-ELECTION OF RETIRING DIRECTORS, (3) PROPOSED RE-APPOINTMENT OF THE EXTERNAL AUDITOR, (4) PROPOSED AGM Information	2024-05-29	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION FOR IBI311 (IGF-1R ANTIBODY) FOR THYROID EYE DISEASE Regulatory Filings	2024-05-21	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024 Share Issue/Capital Change	2024-05-08	English
GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO AN INDEPENDENT NON-EXECUTIVE DIRECTOR Director's Dealing	2024-05-03	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Board/Management Information	2024-05-03	English
APPOINTMENT OF DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEES Board/Management Information	2024-05-03	English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FIRST QUARTER OF 2024 Capital/Financing Update	2024-04-30	English
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2024-04-30	English
2023 ANNUAL REPORT Annual Report FY 2023	2024-04-29	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024 Share Issue/Capital Change	2024-04-08	English
CLARIFICATION ANNOUNCEMENT - GRANT OF RESTRICTED SHARES Share Issue/Capital Change	2024-04-03	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION AND GRANTED PRIORITY REVIEW DESIGNATION FOR SINTILIMAB COMBINATION WITH FRUQUINTINIB FOR THE TRE Regulatory Filings	2024-04-02	English
GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES Director's Dealing	2024-03-24	English
PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY Governance Information	2024-03-20	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 Annual Report FY 2023	2024-03-20	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024 Share Issue/Capital Change	2024-03-06	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SECOND NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR) Regulatory Filings	2024-03-05	English
DATE OF BOARD MEETING Report Publication Announcement	2024-02-29	English
VOLUNTARY ANNOUNCEMENT - THE PHASE 3 CLINICAL STUDY OF IBI311 MET THE PRIMARY ENDPOINT IN TREATING THYROID EYE DISEASE Regulatory Filings	2024-02-20	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Board/Management Information	2024-02-09	English
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE Board/Management Information	2024-02-09	English
VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE FIRST NEW DRUG APPLICATION FOR MAZDUTIDE FOR CHRONIC WEIGHT MANAGEMENT Regulatory Filings	2024-02-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024 Share Issue/Capital Change	2024-02-06	English
INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023 Regulatory Filings	2024-02-06	English
RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER Board/Management Information	2024-02-05	English
VOLUNTARY ANNOUNCEMENT - THE FIRST PHASE 3 CLINICAL TRIAL OF MAZDUTIDE IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS Capital/Financing Update	2024-01-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023 Regulatory Filings	2024-01-05	English

Filings by year

2026 21 filings
2025 56 filings
2024 63 filings
2023 46 filings
2022 58 filings
2021 60 filings
2020 65 filings
2019 54 filings
2018 26 filings